Evolent Health Inc

Evolent Health Inc(EVH)股票分析

$4.495

-0.285 (-6.35%)收盤時

Loading chart…
最高
4.850
開盤
4.790
成交量加權均價
4.57
成交量
1.73M
市值
2.30B
最低
4.360
成交金額
7.91M
企業價值/稅息折舊攤銷前利潤(TTM)
20.54

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

AI 分析 of Evolent Health Inc (EVH)

買進

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

分析師評級(13)

上檔空間 +107.56%
買進
13 買進
0 持有
0 賣出
目前: 4.49
最低
5.00
平均
9.33
最高
16.00

Citi

2026-08-10

目標價

$6

買進

Canaccord

2026-08-10

目標價

$6

買進

TD Cowen

2026-07-28

目標價

$5

買進

Citi

2026-07-23

目標價

—

中性

Canaccord

2026-07-21

目標價

$7

買進

估值指標

Evolent Health Inc(EVH)目前預期本益比為 8.62,5 年平均預期本益比為 68.39。

預期本益比

合理
5 年均值 P/E
68.39
目前P/E
8.62
高估
239.79
低估
-103.01

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-3976.34
目前EV/EBITDA
20.54
高估
24964.91
低估
-32917.58

預期股價營收比

低估
5 年均值 P/S
1.11
目前P/S
0.17
高估
1.83
低估
0.39

Alphio AI 對 EVH 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%EVH

$10.23

情境價格

基

基準

基準 · 50%EVH

$8.49

情境價格

悲

悲觀

悲觀 · 25%EVH

$7.28

情境價格

持有 EVH 的大戶

R

Rock Springs Capital Management LP

+ 持有EVH

-11.57%

3個月報酬率

事件時間軸

2026-08-06 (ET)

08:00:00

Evolent Reports Q2 Revenue of $652.52M, Beating Consensus

08:00:00

2026 Revenue Consensus at $2.5B, Adjusted EBITDA Guidance Tightened to $120M-$135M

2026-05-07 (ET)

07:30:00

Evolent Q1 Revenue at $496.25M, Below Consensus

2026-03-19 (ET)

09:00:00

Evolent Health Appoints Archie Mayani as Chief Product Officer

2026-03-02 (ET)

07:40:00

Oppenheimer Lowers Evolent Health Price Target to $6

資訊

EVH 常見問題 —— 由 Alphio AI 解答

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易